课题基金 / 基金详情

项目摘要

项目成果

Robert Andrew Cramer的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们研究的长期目标是确定人类空气真菌感染最常见致病因子烟曲霉的发病机制。A.尽管烟曲霉的感染率持续上升并且死亡率保持在接近50%,但是需要对这些感染的病理生理学的新的见解。阐明了A.烟曲霉引起的疾病有很大的希望,以确定新的治疗策略,以改善患者的结果。在之前的资助期间,我们将低氧(低氧水平)确定为侵袭性肺曲霉病(IPA)模型中感染部位微环境的关键组成部分。我们的数据表明,缺氧有助于宿主损伤和不良IPA疾病的结果。这些观察结果与许多人类疾病的数据一致,这些疾病将缺氧与负面治疗结果联系起来。由于我们目前不了解缺氧如何影响真菌-宿主相互作用的结果,鉴于缺氧与人类疾病结果之间的显著相关性,这是一个需要了解的问题。本更新建议的目的是确定A.烟曲霉缺氧适应和测试新的氧介导的治疗,以改善IPA的结果。我们的中心假设是,抑制缺氧转录因子SrbA介导的遗传网络可以实现显着改善IPA的结果。本研究的中心假设和目标将通过完成三个具体目标来验证和实现。在目标1中,我们将定义一个新的SrbA依赖性转录因子SrbB有助于一个新的缺氧介导的铁摄取机制所需的真菌毒力的机制。在目标2中,我们将定义SrbA介导的真菌碳代谢产物阻遏在低氧适应和真菌毒力中的先前未知的作用。在目标3中,我们基于令人兴奋的初步数据,表明通过抑制SrbA基因网络来操纵体内氧肺含量可以改善IPA结果。成功完成本提案中的实验将产生对影响真菌缺氧适应机制的新见解,对真菌毒力机制的新见解,以及开发新的非侵入性治疗方法以改善IPA结果。这些拟议的研究预计将成为一系列研究的一部分,这些研究将探索和定义了解真菌如何适应缺氧的巨大治疗机会。
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of our research is to define the pathogenesis mechanisms of the most common causative agent of human airborne fungal infections, Aspergillus fumigatus. As the incidence of disease caused by A. fumigatus continues to rise and the mortality rate remains near 50%, new insights into the pathophysiology of these infections is needed. Elucidating the mechanisms by which A. fumigatus causes disease has great promise to identify new therapeutic strategies to improve patient outcomes. During the prior funding period we identified hypoxia, low oxygen levels, as a critical component of the infection site microenvironment in models of invasive pulmonary aspergillosis (IPA). Our data suggest that hypoxia contributes to host damage and poor IPA disease outcomes. These observations are consistent with data from many human diseases linking hypoxia with negative therapeutic results. Because we currently do not understand how hypoxia influences the outcome of fungal-host interactions, this is a need to know question given the significant association between hypoxia and poor human disease outcomes. The objective of this renewal proposal is to define molecular mechanisms of A. fumigatus hypoxia adaptation and test novel oxygen mediated therapeutic for improvement of IPA outcomes. Our central hypothesis is that inhibition of the hypoxia transcription factor SrbA mediated genetic network can be achieved to significantly improve IPA outcomes. The central hypothesis and objective of this research will be tested and accomplished by completing three specific aims. In aim 1, we will define the mechanism by which a new SrbA dependent transcription factor SrbB contributes to a novel hypoxia mediated iron uptake mechanism required for fungal virulence. In aim 2, we will define a previously unknown role for SrbA mediated fungal carbon catabolite repression in hypoxia adaptation and fungal virulence. In aim 3, we build on exciting preliminary data suggesting that manipulation of in vivo oxygen lung content through inhibition of the SrbA genetic network improves IPA outcomes. Successful completion of the experiments in this proposal will generate novel insights into mechanisms affecting fungal hypoxia adaptation, new insights into mechanisms of fungal virulence, and development of a new non-invasive therapeutic to improve IPA outcomes. These proposed studies are expected to be part of a continuum of research that will explore and define the tremendous therapeutic opportunities in understanding how fungi adapt to hypoxia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
  • 批准号:
    10538624
  • 项目类别:
  • 资助金额:
    $65.3万
  • 财政年份:
    2019
  • 负责人:
    Robert Andrew Cramer
  • 依托单位:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
  • 批准号:
    10615129
  • 项目类别:
  • 资助金额:
    $52.94万
  • 财政年份:
    2019
  • 负责人:
    Robert Andrew Cramer
  • 依托单位:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
  • 批准号:
    10404535
  • 项目类别:
  • 资助金额:
    $52.94万
  • 财政年份:
    2019
  • 负责人:
    Robert Andrew Cramer
  • 依托单位:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
  • 批准号:
    10320401
  • 项目类别:
  • 资助金额:
    $65.3万
  • 财政年份:
    2019
  • 负责人:
    Robert Andrew Cramer
  • 依托单位:
海外基金